ClinicalTrials.gg
RecruitingNCT06672588MASTUpdated Oct 30, 2026

Magnetic Seizure Therapy for Schizophrenia - Trial

An interventional study of Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in Treatment Resistant Schizophrenia, Schizophrenia and Schizoaffective Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 30, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).

Read the detailed description

The study will involve a randomized, double blind, non-inferiority clinical trial with two treatment arms conducted in two academic institutions (the Centre for Addiction and Mental Health (CAMH) in Toronto, and University of British Columbia (UBC) Hospital in Vancouver, British Columbia). The investigators will compare MST to right unilateral ultrabrief pulse ECT (RUL-UB-ECT). Treatment will be administered two to three days per week. Clinical response will be assessed with the 18-item Brief Psychiatric Rating Scale (BPRS). Response will be defined as greater than or equal to 40% decrease in the BPRS positive psychotic symptom subscale (4 items - hallucinatory, behavior, suspiciousness, conceptual disorganization, and unusual thought content). Patients who do not meet response criteria after 15 treatment sessions will be considered non-responders and will cease treatment sessions. The blind will not be broken to participants until the completion of the entire study.

02

Conditions studied

  • Treatment Resistant Schizophrenia
  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Schizoaffective Disorder
  • Treatment Resistant Schizophrenia
  • Electroconvulsive Therapy
  • Magnetic Seizure Therapy
  • Convulsive Therapy
03

In context

Schizophrenia, Treatment-Resistant

54 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 23 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 46 interventional studies indexed under Schizophrenia, Treatment-Resistant.

Browse Schizophrenia, Treatment-Resistant studies →

Lead sponsor

Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are inpatients or outpatients;
  2. demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR);
  3. have a diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0);
  4. are 18 years of age or older;
  5. have demonstrated resistance to at least 2 antipsychotics of 600 mg of chlorpromazine equivalents for at least 6 weeks;
  6. have a BPRS score at baseline of at least moderate severity (>4) on one of the four psychotic items (i.e., hallucinatory behavior, suspiciousness, conceptual disorganization, unusual thought content) or at least 12 on these 4 items combined;
  7. are considered to be appropriate to receive convulsive therapy as assessed by an ECT attending psychiatrist and a consultant anaesthesiologist;
  8. are on an antipsychotic at an adequate dose and are agreeable to keeping their current antipsychotic treatment constant during the acute phase of the intervention;
  9. are able to adhere to the intervention schedule;
  10. meet the MST safety criteria;
  11. If a woman of : is willing to provide a negative pregnancy test and agrees not to become pregnant during trial participation.

Exclusion criteria

Exclusion Criteria:

  1. have a history of MINI diagnosis of a substance use disorder (other than nicotine and caffeine) within the past three months;
  2. have received electroconvulsive therapy (ECT) in the past six (6) months;
  3. have a concomitant major unstable medical illness;
  4. are pregnant or intend to get pregnant during the study;
  5. have probable dementia based on study investigator assessment;
  6. have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm;
  7. present with a serious medical condition,
  8. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  9. require a benzodiazepine with a dose > lorazepam 2 mg/day or equivalent or any anticonvulsant due to the potential of these medications to limit the efficacy of both MST and ECT;
  10. are unable to communicate in English fluently enough to complete the neuropsychological tests;
  11. have a non-correctable sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Magnetic Seizure Therapy (MST)

    MST treatments will be administered using the MagPro MST with Cool TwinCoil.

    Device: Magnetic Seizure Therapy (MST)

  • Active comparator
    Electroconvulsive Therapy (ECT)

    ECT treatments will be administered using the MECTA Sigma.

    Device: Electroconvulsive Therapy (ECT)

Interventions

  • DeviceMagnetic Seizure Therapy (MST)

    MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

    Also known as: MST

  • DeviceElectroconvulsive Therapy (ECT)

    In the ECT arm treatment, the MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

    Also known as: ECT

06

What researchers measure

Primary outcomes

  1. Brief Psychiatric Rating Scale (BPRS) Response (18-Version)

    The scale is used to quantify psychiatric symptoms such as anxiety, depression, hallucinations, and unusual behaviours. The scale range is 18-126. A lower score indicates lower severity in anxiety, depression, and positive psychotic symptoms. A higher score indicates higher severity in negative and positive psychotic symptoms.

    Time frame: Greater than 8 treatments (2.5 weeks)

  2. MATRICS™ Consensus Cognitive Battery (MCCB)

    The MCCB Assessments: The battery of cognitive assessments (ten in total) is intended to provide evaluation of key cognitive domains relevant to schizophrenia and related disorders and be a measure of cognitive change before and after the treatment course. The ten tasks focus on the following cognitive domains: speed of processing; attention/vigilance; working memory; verbal learning; visual learning; reasoning and problem solving; and social cognition.

    Time frame: Greater than 8 treatments (2.5 weeks)

Secondary outcomes

  1. Scale for Suicidal Ideation (SSI)

    This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas. The scale range is 0 - 38 (total score). Lower scores indicate lower severity of suicidal ideation (i.e., better outcome). Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome).

    Time frame: Greater than 8 treatments (2.5 weeks)

  2. The Calgary Depression Scale for Schizophrenia (CDSS)

    CDSS is a nine item clinician rated outcome measure that assesses the level of depression in people with schizophrenia. It distinguishes depressive symptoms from negative positive and extrapyramidal symptoms. The scale range is 0 - 27. A lower score indicates lower severity in depressive symptoms. A higher score indicates higher severity in depressive symptoms.

    Time frame: Greater than 8 treatments (2.5 weeks)

  3. Autobiographical Memory Test (AMT)

    Interviewer-rated measure with 10 items that indexes autobiographical memory recall and specificity.

    Time frame: Greater than 8 treatments (2.5 weeks)

  4. Montreal Cognitive Assessment (MoCA)

    The MoCA is a 30-point screening test that takes approximately 10 minutes to administer. It assesses executive functioning, visuospatial abilities, memory, attention, working memory, language, and orientation.

    Time frame: Greater than 8 treatments (2.5 weeks)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data from this project will be used for future research by internal and external project collaborators. Deidentified participant data along with data dictionaries will be made available and to gain access data requestors will need to sign a data access agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 12 months and ending 3 years after publication of the primary outcome paper.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Apr 22, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • Addedhave received electroconvulsive therapy (ECT) in the past six (6) months;
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • Addedhave received electroconvulsive therapy (ECT) in the past six (6) months;
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06672588
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Apr 22, 2025
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Daniel Blumberger, MD., MSc.
Contact
daniel.blumberger@camh.ca
416-535-8501 ext. 33662
Hannah Taalman, MSc.
Contact
hannah.taalman@camh.ca
416-535-8501 ext. 30990
Daniel Blumberger, M.D., MSc.
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion